2023 Presentations

Friday, March 17th Presentations

CONCERT NETWORK (Cabinet & Caucus)

How to set up Cellular Therapies at your institution – Ruemu Birhiray, MD, CEO, Indy Hematology Education, Inc.

Cellular Therapy for Leukemias; Efficacy and Managing Adverse Reactions – Evan Chen, MD, Dana-Farber Cancer Institute

Cellular Therapy for Myeloma; Efficacy and Managing Adverse Reactions – Rafat Abnour, MD, Indiana University

Cellular Therapy for Lymphoma; Efficacy and Managing Adverse Reactions – Matt Lunning DO, FACP, University of Nebraska Medical Center

Financial Considerations for Cellular Therapy in Community Oncology – Susan Weidner, IntrinsiQ Specialty Solutions, Inc.

Operational Protocol and Standard Operating Procedures – Brooke Peters, Pharm D, American Oncology Network, LLC

CONCERT NETWORK Audio

album-art
00:00

An Evening with the Experts (Grand 5)

The Overview: Emerging Treatment Strategies for Blood Cancers – Dr. Ruemu Birhiray, MD

Cellular Therapy and Hematopoietic Stem Cell Transplantation of Blood Cancers and Diseases – Dr. Richard Childs, MD

Art Therapy and You, Including Art in the Healing Process – Meaghan Wiggins, MA, LMHCA

BREAK OUT SESSIONS
Dr. Kenneth Anderson, MD – Multiple Myeloma

Dr. Morie Gertz, MD, MACP – Waldenstrom’s Macroglobulinemia

Dr. William Wierda, MD, PhD – Chronic Lymphocytic Leukemia

Dr. Gilles Salles, MD, PhD – Lymphomas

Dr. Angela Fleischman, MD, PhD – Myeloproliferative Neoplasms

Saturday, March 18th Presentations

Symposium - Physicians (Grand 4&5)

7:55 – 8:20 AM
State of the Art: 2023: Emerging Therapies in Hematologic Malignancies – Ruemu E. Birhiray, MD

8:20 – 8:30 AM
Conversations with the 2023 President of the American Society of Hematology
Robert Brodsky, MD

8:30 – 9:00 AM
Improving Outcomes with Current Therapies in Acute Myeloid Leukemia and Acute Promyelocytic Leukemia: What we Recommend in 2023 – Martin Tallman, MD

9:00 – 9:30 AM
Apollo and The Indianapolis Oracle: Prognostication and Treatment of Myelodysplastic Syndromes – Richard Stone, MD

9:30 – 10:00 AM
Treatment Goals in Chronic Myeloid Leukemia: Managing Resistance, Recurrence and Discontinuation – Richard Larson, MD

10:15-10:45 AM
Emerging and Current Treatment of Multiple Myeloma: What Should We Know and What Should We Do – Kenneth Anderson, MD

10:45 –11:15 AM
Hematopoietic Transplantation and Cellular Therapies – Richard Childs, MD

11:15 -11:45 AM
Managing the Benign Hematology Consult: Treatment Recommendations for Coagulopathy, Cytosis and Cytopenia – Craig Kessler, MD, MACP

12:00 -12:30 PM
Myelofibrosis Chronic and Blast Phase: 2023 Algorithms for Risk Stratification and Treatment – Ayalew Tefferi, MD

12:30 -1:00 PM
Polycythemia Vera, Philadelphia Chromosome Negative Myeloproliferative and FGFR Mutant Myeloid Neoplasms – Angela Fleischman, MD, PhD

2:00 – 2:45 PM
T. Howard Lee Keynote Lecture: 20 Years of Indy Hematology Review and The Cure is in: Managing Indolent and Mantle Cell Lymphomas with Targeted and Cellular Therapies in 2023 – Gilles Salles, MD, PhD

2:45 – 3:15 PM
Current Controversies and Recommendations for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: The Indy Hematology Review Recommendations for 2023 – Wendy Stock, MD, MA

3:15 – 3:45 PM
Emerging Therapy for Relapsed and Refractory Chronic Lymphocytic Leukemia – William Wierda, MD, PhD

4:00 – 4:30 PM
Annual Steven Coutre Chronic Lymphocytic Leukemia Memorial Lecture: Therapeutic Options in CLL in 2023: Choosing Wisely: Initial Therapy in CLL – Jennifer Woyach, MD

4:30 – 5:00 PM
Jumping On a Moving Train: Emerging and Current Treatment for Hodgkin’s Lymphoma – Matthew Lunning D.O., FACP

5:00 – 5:30 PM
Advancing Therapeutic Outcomes in Aggressive B and T Cell Lymphomas – Tycel Phillips, MD

5:30 – 6:00 PM
Beyond Hyperviscosity: 80 Years and Counting, Treatment of Waldenstrom’s Macroglobulinemia – Steven Treon, MD, MA, PhD, FACP, FRCP

6:00- 6:30 PM
The Great Debate: Controversies in The Initial Therapy of Multiple Myeloma: To Transplant or Not When Minimal Residual Disease has been Achieved as Initial Therapy for Multiple Myeloma Monitoring and Rescuing the MRD Negative Patient with Multiple Myeloma After Initial Therapy – Joseph Mikhael MD, MEd, FRCPC, FACP

Transplanting the MRD Negative Myeloma Patients for a Deeper Remission After Initial Therapy – Saad Usmani, MD, MBA, FACP

6:30 –7:00 PM
Q/A and Panel Discussion – Take Home Messages: Achieving Tomorrow’s Outcomes Through Education Today
Dr. Ruemu E. Birhiray, MD – Chair and Moderator
Dr. Michael Wiemann, MD, FACP – Co-Chair
William Wierda, MD, PhD – Chronic Lymphocytic Leukemia
Rami Komrokji, MD – Acute Leukemias and Myelodysplastic Syndromes
Ruben Mesa, MD, FACP – Myeloproliferative Neoplasms
Charles Schiffer, MD – Acute Lymphoblastic Leukemia
Morie Gertz, MD, MACP – Plasma Cell Neoplasms and Amyloidosis

7:30 – 8:45 PM
Hematologic Malignancies Town Hall

Nursing & Allied Providers (Capitol 2)

7:55 – 8:20 AM
State of the Art: 2023: Emerging Therapies in Hematologic Malignancies – Ruemu E. Birhiray, MD

8:40 – 9:05 AM
Understanding and Managing Immune Effector Toxicities in Hematologic Toxicities – David Reeves, PharmD, BCOP

9:05 – 9:30 AM
Management of Long-Term Survivors of Hematologic Malignancies – Sandra Garofalo, MS, APRN, AOCNP

9:30 –10:00 AM
Managing Disorders of the Benign Hematology Patient – Craig Kessler, MD, MACP

10:15 – 10:45 AM
Understanding the Diagnosis and Treatment of Plasma Cell Disorders – Saad Usmani, MD, MBA, FACP

10:45 – 11:15 AM
Emerging and Current Treatment of Amyloidosis and Waldenstrom’s Macroglobulinemia – Morie Gertz, MD, MACP

11:30 – 11:55 AM
Recognizing Toxicities of Oral Oncolytics in the Management of Hematologic Malignancies – Kristi Orbaugh, RN, MSN, RNP, AOCN

11:55 – 12:25 PM
Diagnosis and Treatment of Myeloproliferative Neoplasms – Ruben Mesa, MD, FACP

12:25 – 12:55 PM
Current and Emerging Therapies for Acute Leukemias and Myelodysplastic Syndromes – Richard Larson, MD